Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Is Pfizer (PFE) a Buy as Wall Street Analysts Look Optimistic?
02:37pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Based on the average brokerage recommendation (ABR), Pfizer (PFE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this hi
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
12:03pm, Thursday, 08'th Dec 2022
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
12:03pm, Thursday, 08'th Dec 2022
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
02:00pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
GSK and Sanofi shares surge after Florida ruling dismisses Zantac lawsuits in what one analyst describes as 'best-case scenario'
11:06am, Wednesday, 07'th Dec 2022 MarketWatch
After a Florida judge threw out thousands of lawsuits involving heartburn drug Zantac on Tuesday, causing a number of pharmaceutical stocks to soar, analysts are bullish about forthcoming state cases.
FDA expected to decide on Pfizer RSV vaccine for older adults by May 2023
10:37am, Wednesday, 07'th Dec 2022
Pfizer said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
10:32am, Wednesday, 07'th Dec 2022
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
FDA set to decide on Pfizer's RSV vaccine by May
07:44am, Wednesday, 07'th Dec 2022
Pfizer Inc. PFE, -2.01% said Wednesday that its experimental respiratory syncytial virus vaccine received Priority Review from the Food and Drug Administration. The drug maker is seeking FDA approval
Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants
01:52pm, Tuesday, 06'th Dec 2022 Zacks Investment Research
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
01:16pm, Tuesday, 06'th Dec 2022 Zacks Investment Research
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history
11:50am, Tuesday, 06'th Dec 2022
Pfizer asked a federal court in Boston on Monday to dismiss Moderna's lawsuit seeking monetary damages for alleged patent violations related to the Covid vaccine.
Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants
10:32am, Tuesday, 06'th Dec 2022
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
Pfizer legal woes continue with battle against Moderna
04:58am, Tuesday, 06'th Dec 2022
Pfizer Inc (NYSE:PFE) and BioNTech have moved to countersue rival Moderna Therapeutics Inc in a legal battle over the development of each company's respective Covid-19 vaccines. Moderna sued the du
Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?
01:28am, Tuesday, 06'th Dec 2022 Zacks Investment Research
Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong i
Relative Strength Found Within These 3 Medical Stocks
10:35pm, Monday, 05'th Dec 2022 Zacks Investment Research
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
